

AstraZeneca Development Pipeline

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			PC	1	2	3	MAA	NDA
Cardiovascular								
NCEs								
<i>Exanta</i>	thrombin inhibitor	prevention of VTE					Launched	Filed*
<i>Exanta</i> SC formulation	thrombin inhibitor (sc)	prevention of VTE					Launched	>2007
<i>Galida</i>	PPAR agonist	diabetes /metabolic syndrome					2007	2007
AZD6140	ADP receptor antagonist	arterial thrombosis					>2007	>2007
AZD7009	anti-arrhythmic IV	AF – conversion					>2007	>2007
AZD7009	anti-arrhythmic oral	AF – maintenance					>2007	>2007
AZD9684	CPU inhibitor	thrombosis					>2007	>2007
AZD0837	thrombin inhibitor	thrombosis					>2007	>2007
AZD7806	IBAT inhibitor	dyslipidaemia					>2007	>2007
AZD4619		dyslipidaemia					>2007	>2007
AZD6610		dyslipidaemia/diabetes					>2007	>2007
AZD8294		dyslipidaemia					>2007	>2007
AZD8677		dyslipidaemia/diabetes					>2007	>2007
AZD8450		dyslipidaemia					>2007	>2007
AZD6370		diabetes					>2007	>2007
Line Extensions								
<i>Atacand</i>	angiotensin II antagonist	CHF outcomes (CHARM study)					Approved	Filed
		diabetic retinopathy					>2007	>2007
<i>Crestor</i>	statin	atheroma					2H 2006	2H 2006
		outcomes CHF					>2007	>2007
		outcomes renal					2007	2007
<i>Seloken/Toprol-XL</i>	beta blocker	HCTZ combination						3Q 2005
<i>Exanta</i>	thrombin inhibitor	prevention of stroke in AF					Filed	Filed*
		treatment of VTE					Filed	>2007
		arterial/post MI					>2007	>2007

*Discussions are ongoing with the FDA to determine if there is now a realistic prospect of bringing *Exanta* to the US market. The NDA file remains open.

Gastrointestinal

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			PC	1	2	3	MAA	NDA
NCEs								
AZD0865	P-CAB	acid-related GI disease					2007	2007
AZD7371		functional GI disease					>2007	>2007
AZD3355	inhibitor of TLESR	GERD					>2007	>2007
AZD9343	inhibitor of TLESR	GERD					>2007	>2007
AZD5745		acid-related GI disease					>2007	>2007
AZD8081		functional GI disease					>2007	>2007
Line Extensions								
<i>Nexium</i>	proton pump inhibitor	NSAID GI side effects – symptom resolution					Promotable*	Filed
		parenteral formulation					Launched	Filed
		NSAID GI side effects – ulcer prevention					Launched	Launched
		NSAID GI side effects – ulcer healing					Launched	Filed
		extra-oesophageal reflux disease					>2007	>2007

*Authorities stated these symptoms were already captured within the GERD label. Text stating “No clinical interaction with naproxen or rofecoxib” was approved.

Infection

Compound	Mechanism	Areas under investigation	Phase	Estimated filing date
<i>Merrem</i>	carbapenem antibiotic	skin and soft tissue infections		Filed

Neuroscience

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			PC	1	2	3	MAA	NDA
NCEs								
<i>Cerovive</i>	free radical trapping agent	stroke					2H 2006	2H 2006
AZD7371		overactive bladder					>2007	>2007
AZD8129 (AR-A2)	5HT _{1B} antagonist	anxiety/depression					>2007	>2007
AZD4282	NMDA antagonist	neuropathic pain					>2007	>2007
AZD3102		Alzheimer’s disease					>2007	>2007
AZD1080		Alzheimer’s disease					>2007	>2007
AZD9272		neuropathic pain					>2007	>2007
AZD2327		anxiety					>2007	>2007
AZD5904		multiple sclerosis					>2007	>2007
AZD6538		neuropathic pain					>2007	>2007
Line Extensions								
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	sustained release					1H 2006	1H 2006
		bipolar maintenance					2007	2007
		bipolar depression					2007	1H 2006

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			PC	1	2	3	MAA	NDA
Oncology								
NCEs								
<i>Iressa</i>	EGFR-TKI	NSCLC					Withdrawn	Launched
ZD6474	angiogenesis inhibitor (VEGFR-TKI)	solid tumours					>2007	>2007
ZD4054	endothelin A receptor antagonist	solid tumours					>2007	>2007
AZD2171	angiogenesis inhibitor (VEGFR-TKI)	solid tumours					>2007	>2007
AZD3409	farnesyl-transferase inhibitor	solid tumours					>2007	>2007
AZD0530	SRC kinase inhibitor	solid tumours and haematological malignancies					>2007	>2007
AZD5438	selective cyclin dependent kinase inhibitor	solid tumours					>2007	>2007
AZD6244	MEK inhibitor	solid tumours					>2007	>2007
ZD6126	vascular targeting agent	solid tumours					>2007	>2007
AZD4440	vascular targeting agent	solid tumours					>2007	>2007
AZD9935	angiogenesis inhibitor (VEGFR-TKI)	solid tumours					>2007	>2007
AZD0424	SRC kinase inhibitor	solid tumours					>2007	>2007
AZD1152	aurora kinase inhibitor	solid tumours and haematological malignancies					>2007	>2007
AZD4769		solid tumours					>2007	>2007
AZD3841		solid tumours					>2007	>2007
AZD8931		solid tumours					>2007	>2007
Line Extensions								
<i>Faslodex</i>	oestrogen receptor antagonist	1st line advanced breast cancer					>2007	>2007
<i>Iressa</i>	EGFR-TKI	head and neck cancer*					2H 2006	2H 2006
		breast cancer*					>2007	>2007
		colorectal cancer*					>2007	>2007

* Under review

Respiratory and Inflammation

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			PC	1	2	3	MAA	NDA
NCEs								
AZD9056	ion channel blocker	rheumatoid arthritis					>2007	>2007
AZD9056	ion channel blocker	osteoarthritis					>2007	>2007
AZD8309	chemokine receptor antagonist	rheumatoid arthritis					>2007	>2007
AZD8955	collagenase inhibitor	osteoarthritis					>2007	>2007
AZD8309	chemokine receptor antagonist	COPD					>2007	>2007
AZD3778	chemokine receptor antagonist	asthma/rhinitis					>2007	>2007
AZD9056	ion channel blocker	COPD					>2007	>2007
AZD3342	protease inhibitor	COPD					>2007	>2007
AZD6067	protease inhibitor	COPD					>2007	>2007
AZD2098		asthma					>2007	>2007
AZD1981		asthma					>2007	>2007
AZD0902	ion channel blocker	rheumatoid arthritis					>2007	>2007
AZD6703		rheumatoid arthritis					>2007	>2007
AZD6357		osteoarthritis					>2007	>2007
AZD7928		COPD					>2007	>2007
AZD2914		COPD					>2007	>2007
AZD2392		asthma/rhinitis					>2007	>2007
AZD1744		asthma/rhinitis					>2007	>2007
AZD5672		rheumatoid arthritis					>2007	>2007
Line Extensions								
<i>Symbicort Turbuhaler</i>	inhaled steroid/fast onset, long-acting beta ₂ agonist	single therapy for asthma					2H 2005	
<i>Symbicort pMDI</i>	inhaled steroid/fast onset, long-acting beta ₂ agonist	asthma					Filed	2Q/3Q 2005*
		COPD					Filed	2007

* The FDA has identified some issues associated with the inhaler that require the generation of additional chemistry and manufacturing data or possible modification of the device in order to achieve approval.

Comments – As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Abbreviations:

5HT – 5-hydroxytryptamine (serotonin)
 5HT_{1B} – 1B subtype of 5HT receptor
 5HT₂ – 2 subtype of 5HT receptor
 ADP⁺ – adenosine diphosphate
 AF – atrial fibrillation
 CHF – congestive heart failure
 COPD – chronic obstructive pulmonary disease
 CPU – carboxy peptidase-U
 D₂ – 2 subtype of dopamine receptor
 EGFR-TKI – epidermal growth factor receptor-tyrosine kinase inhibitor
 GERD – gastro-oesophageal reflux disease
 GI – gastrointestinal
 H – half year
 HCTZ – hydrochlorothiazide
 IBAT – ileal bile acid transport

IV – intravenous
 MAA – marketing authorisation application (Europe)
 MEK – mitogen activated (extra-cellular signal-regulated kinase) kinase
 MI – myocardial infarction
 NCE – new chemical entity
 NDA – new drug application (US)
 NMDA – N-methyl-D-aspartate
 NSAID – non-steroidal anti-inflammatory drug
 NSCLC – non-small cell lung cancer
 P-CAB – potassium-competitive acid blocker
 PC – pre-clinical; candidate drug accepted for development but not yet administered to man
 pMDI – pressurised metered dose inhaler
 PPAR – peroxisome proliferator-activated receptor
 Q – quarter
 sc – subcutaneous

TLESR – transient lower oesophageal sphincter relaxations
 VEGFR-TKI – vascular endothelial cell growth factor receptor-tyrosine kinase inhibitor
 VTE – venous thromboembolism
 >2007 – not earlier than 2008

Discontinued projects:

AZD4750 – multiple sclerosis
 AZD5455 – anxiety
 AZD0328 – Alzheimer’s disease
Seroquel – granules
 AZD2858 – Alzheimer’s disease
 ZD0947 – overactive bladder
 AZD0902 – COPD
 AZD0303 – thrombolysis